Navigation Links
Audet & Partners, LLP Files First Raptiva Lawsuit After Announced Withdrawal
Date:4/9/2009

Audet & Partners, LLP, a San Francisco, California-based trial law firm, filed the first complaint against Genentech arising out of the recently announced withdrawal of Raptiva medication. Filed in Alameda Superior Court, the complaint seeks general and punitive damages.

San Francisco, CA (PRWEB) April 9, 2009 -- Audet & Partners, LLP, a San Francisco, California-based trial law firm, filed the first complaint against Genentech arising out of the recently announced withdrawal of Raptiva medication. Filed in Alameda Superior Court (Case #rg09-446158), the complaint seeks general and punitive damages.

Raptiva is a medication used to treat severe to moderate psoriasis and works by suppressing the immune system. According to allegations in the complaint filed by Audet & Partners, LLP Raptiva allegedly causes a number of serious life-threatening infections, including encephalitis, viral meningitis and a rare brain infection known as progressive multifocal leukoencephalopathy (PML). At least three and possibly four cases of PML brain infections have been confirmed by the FDA.

Due to safety concerns, Raptiva already is suspended from the market in both Europe and Canada, and as of April 8, 2009, Genentech announced a phased withdrawal of Raptiva from the United States market.

"We have a number of clients who have contacted our firm over the past couple of months regarding Raptiva, and this is one of the first cases filed in the United States," noted William M. Audet, managing partner of Audet & Partners, LLP, "We expect that more cases will be filed by our firm as our investigation continues."

In the complaint, Plaintiff Mary Hedrick alleges that she suffered herpes viral encephalitis, a rare brain infection, as a result of being treated with Raptiva. This left her with permanent brain and nervous system damage requiring her to undergo intensive rehabilitation to relearn how to walk and speak. Plaintiff Shirley Boxell is suing on behalf of her daughter, Megan, who died of a brain infection at age 26, after taking Raptiva for one year. Plaintiff Bruce Harwell has suffered from severe leucopenia, as well as other injuries, allegedly due to Raptiva.

"All of the plaintiffs in this case have suffered serious injury while taking Raptiva, a monoclonal antibody that inhibits T-cell activity," stated Susanne Scovern, a trial attorney at Audet & Partners, LLP. "No one would choose to take a life-threatening drug for a non-life-threatening injury. The dangerous side effects of Raptiva far outweighed the good it did to treat psoriasis," she stated.

Audet & Partners, LLP, (221 Main Street, Suite 1460, San Francisco, CA 94105, 415.982.1776) a San Francisco-based law firm, represents individuals, governmental entities, small businesses and shareholders in product liability, tort, negligence, consumer, construction defect, investment fraud, securities, insider trading, antitrust, environmental, whistle blower, aviation and employment cases. The founding partner, William M. Audet, has served as court-approved lead counsel in dozens of federal and state cases throughout the United States.

# # #

Read the full story at http://www.prweb.com/releases/raptiva/lawsuit/prweb2315484.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Get Your Fruits & Veggies: CDC
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Story ideas from molecular & cellular proteomics
4. Job picture for 2006 chemistry grads reasonably good, C&EN reports
5. Debut issue of Foot & Ankle Specialist
6. Congressional R&D Caucus co-chairs join scientists, engineers and graduate students
7. IU Health & Wellness: Research and insights from Indiana University
8. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
9. European Society of Human Reproduction & Embryology 24th annual meeting
10. IU Health & Wellness: New research findings from the Kinsey Institute
11. Riley Hospital for Children & Capital Institute of Pediatrics become international sister hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 12, 2016 , ... The Journal of Pain Research has seen ... SJR uses data taken from the Scopus database (Elsevier B.V.) and is a measure ... by the journal over a three year period and also the importance of the ...
(Date:2/11/2016)... ... 11, 2016 , ... The president released a FY 2017 budget request on ... more of the cost burden to military beneficiaries. , MOAA’s president, retired Air ... budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health and ... for their simultaneous grand openings in March. All seven practices are set to ... wondering, is reversing diabetes possible? According to this 2011 CNN article it is ...
(Date:2/11/2016)... ... 2016 , ... Thermi™, a world leader in thermistor-regulated energy ... promotions of Allison Kelly to executive vice president of the company’s new North ... North American capital sales, and Wendy Oseas to vice president of global marketing. ...
(Date:2/11/2016)... ... 11, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health ... value-based health benefits program Connected Care, will discuss the challenges they faced (and ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Ill. , Feb. 11, 2016  AbbVie, ... the AbbVie Rheumatology Scholarship, designed to provide financial ... disease as they pursue higher education goals. Fifteen ... for the 2016-2017 school year. The AbbVie Rheumatology ... Tracie Haas , vice president, corporate social responsibility, ...
(Date:2/11/2016)... Feb. 11, 2016  Community pharmacists can help improve ... the pharmacy through a custom-built medication synchronization program, Cardinal ... and owner at Schieber Family Pharmacy in ... a lot of patients enrolled in this medication synchronization ... a win for the patient, and it,s a win ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists from ... method that opens the door to genetic analysis ... have been impossible to isolate with 100 percent ... specific tumor types in various stages of development, ... of these cells that are clinically relevant, and ...
Breaking Medicine Technology: